| Name | Cofirasersen |
|---|
| Description | Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C172H218N57O88P15S15 |
|---|---|
| Molecular Weight | 5437.55 |